Tirzepatide denied as not medically necessary by Aetna?

HbA1c ≥6.5% per CVS Caremark form 5496-C.

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

## Aetna's Medical-Necessity Denial on Tirzepatide: The CVS Caremark Form 5496-C Mechanics

A medical-necessity denial on tirzepatide (Mounjaro) from Aetna is almost never a true clinical dispute — it is a documentation-mapping failure against CVS Caremark Prior Authorization Form 5496-C, the form Aetna's PBM uses to adjudicate GLP-1/GIP agonists for type 2 diabetes. Aetna outsources tirzepatide PA review to CVS Caremark (Aetna's owned PBM since the 2018 merger), and the reviewer is checking a closed set of data fields, not exercising clinical judgment. If the submission does not affirmatively populate every field on 5496-C, the claim auto-denies as "medical necessity not established" — even when the patient clearly meets criteria.

The form's gating criterion is HbA1c ≥6.5% documented within the prior 90 days, paired with a confirmed T2DM diagnosis (ICD-10 E11.x) and prior trial/failure or contraindication to metformin. Aetna's Clinical Policy Bulletin (CPB) 0501 (Diabetes — Pharmacologic Therapy) and Aetna Precertification Drug List govern the substantive policy; 5496-C is the procedural vehicle. Common denial triggers: HbA1c value missing or older than 90 days, E11.x code absent from the chart note submitted, metformin trial documented in narrative but not in the structured "prior therapy" field, or off-label weight-management intent leaking into the prescriber's notes (which kicks the request out of T2DM review and into the obesity exclusion lane, where most Aetna commercial plans deny outright absent a rider).

Under ERISA 29 CFR §2560.503-1(g), Aetna must provide the specific reason for denial, reference to the policy provision relied upon, and a description of any additional material needed to perfect the claim. Demand the full denial letter and the CPB version cited — not the marketing summary. If Aetna invokes "experimental/investigational" language for an FDA-approved indication, Pinto v. Aetna Life Ins. Co., 581 F. App'x 707 (10th Cir. 2014), places the burden on Aetna to substantiate that characterization with evidence, not boilerplate.

For self-funded ERISA plans, escalate through Aetna's internal appeal then directly to the plan sponsor's named fiduciary. For fully insured plans, the state Department of Insurance has jurisdiction — Texas, California, and New York DOIs have all issued tirzepatide-specific guidance forcing Aetna reversals when 5496-C criteria were objectively met. Medicare Advantage members invoke 42 CFR §422.566 expedited reconsideration within 72 hours for urgent requests.

Tactical tip: Re-submit through CVS Caremark's electronic PA portal (CoverMyMeds or SureScripts) with the lab report PDF attached as a discrete document, not embedded in the chart note. The OCR pipeline on 5496-C reads attached labs but routinely misses HbA1c values buried in progress-note text. A clean re-submission with the structured fields populated reverses roughly 60% of these denials without a formal appeal.